 |
 |
|||
| High-throughput Natural Products Chemistry | ||||
|
||||
| Sequoia Sciences has an unparalleled collection of structurally diverse natural product compounds isolated from plants. From this collection, Sequoia has identified compounds that may potentially provide new and alternative treatments for acute bacterial infections and chronic infections involving bacterial biofilms. Based upon these results, Sequoia Sciences is embarking on preclinical development programs with the goals of addressing the unmet medical needs for the treatment of lung infections in Cystic Fibrosis patients and chronic urinary tract infections. These programs consist of small molecules targeting gram-positive and gram-negative infections and vaccines for the treatment and prevention of chronic urinary tract infections. To this purpose, we are engaged in collaborations with other laboratories and universities. Our goal is to improve the quality of life for those individuals significantly affected by acute bacterial infections and chronic infections involving bacterial biofilms. Recent Publications | See All Jan. 2008: The Biology and Future Prospects of Antivirulence Therapies, Nature Rev. Microbiology
May, 2007: Asiatic Acid and Corosolic Acid Enhance the Susceptibility of Pseudomonas aeruginosa Biofilms to Tobramycin, Antimicrobial Agents and Chemotherapy
May, 2007: Stilbenes from the Orchid Phragmipedium sp., Journal of Natural Products
Copyright ©2008 Sequoia Sciences
|
||||